(Q57702367)

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Time to abandon microalbuminuria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Emerging drugs for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Slowing nephropathy progression: focus on proteinuria reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Preventing microalbuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Prevention of loss of renal function over time in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Beneficial impact of spironolactone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Intensified inhibition of renin-angiotensin system: a way to improve renal protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

21 January 2018

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Clinical practice. Initial management of glycemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Troglitazone-induced liver failure: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

RAGE and its ligands: a lasting memory in diabetic complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Endothelins in the control of cardiovascular and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Protein kinase C activation and the development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Proteomic patterns and prediction of glomerulosclerosis and its mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Effect of high dose ramipril with or without indomethacin on glomerular selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Role of remission clinics in the longitudinal treatment of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Smoking as a risk factor for end-stage renal failure in men with primary renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487

Salt: its role in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.10.1487